NO20043068L - Kondenserte heterocykliske succinimidforbindelser og analoger derav, modulatorer for nukleaer hormonreseptorfunksjon - Google Patents

Kondenserte heterocykliske succinimidforbindelser og analoger derav, modulatorer for nukleaer hormonreseptorfunksjon

Info

Publication number
NO20043068L
NO20043068L NO20043068A NO20043068A NO20043068L NO 20043068 L NO20043068 L NO 20043068L NO 20043068 A NO20043068 A NO 20043068A NO 20043068 A NO20043068 A NO 20043068A NO 20043068 L NO20043068 L NO 20043068L
Authority
NO
Norway
Prior art keywords
modulators
analogs
hormone receptor
receptor function
condensed heterocyclic
Prior art date
Application number
NO20043068A
Other languages
English (en)
Norwegian (no)
Inventor
Raj Narain Misra
Toomas Mitt
Mark Ernest Salvati
Hai-Yun Xiao
Dacia A Pickering
Aberra Fura
Wenying Li
Ramesh N Patel
Ronald L Hanson
Soren Giese
James Aaron Balog
Jacques Y Roberge
James R Corte
Steven H Spergel
Richard A Rampulla
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20043068L publication Critical patent/NO20043068L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043068A 2001-12-19 2004-07-16 Kondenserte heterocykliske succinimidforbindelser og analoger derav, modulatorer for nukleaer hormonreseptorfunksjon NO20043068L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2511601A 2001-12-19 2001-12-19
PCT/US2002/040598 WO2003062241A1 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (1)

Publication Number Publication Date
NO20043068L true NO20043068L (no) 2004-09-08

Family

ID=27609007

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043068A NO20043068L (no) 2001-12-19 2004-07-16 Kondenserte heterocykliske succinimidforbindelser og analoger derav, modulatorer for nukleaer hormonreseptorfunksjon

Country Status (31)

Country Link
EP (1) EP1458723B1 (pl)
JP (1) JP2005523257A (pl)
KR (1) KR20040086248A (pl)
CN (1) CN1589271A (pl)
AR (1) AR037950A1 (pl)
AT (1) ATE411319T1 (pl)
AU (1) AU2002361785B2 (pl)
BR (1) BR0215281A (pl)
CA (1) CA2471342A1 (pl)
CO (1) CO5640082A2 (pl)
DE (1) DE60229435D1 (pl)
DK (1) DK1458723T3 (pl)
ES (1) ES2314127T3 (pl)
GE (1) GEP20063817B (pl)
HR (1) HRP20040567A2 (pl)
HU (1) HUP0402554A3 (pl)
IL (1) IL162547A0 (pl)
IS (1) IS7324A (pl)
MX (1) MXPA04005876A (pl)
NO (1) NO20043068L (pl)
NZ (1) NZ533471A (pl)
PL (1) PL370904A1 (pl)
PT (1) PT1458723E (pl)
RU (1) RU2330038C2 (pl)
SI (1) SI1458723T1 (pl)
TW (1) TWI263640B (pl)
UA (1) UA78265C2 (pl)
UY (1) UY27595A1 (pl)
WO (1) WO2003062241A1 (pl)
YU (1) YU53604A (pl)
ZA (1) ZA200404812B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202264B2 (en) 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
FR2860793A1 (fr) * 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
WO2005049621A1 (en) * 2003-11-13 2005-06-02 Isis Pharmaceuticals, Inc. 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP4880583B2 (ja) * 2004-03-17 2012-02-22 ファイザー・プロダクツ・インク 新規なベンジル（ベンジリデン）−ラクタム誘導体
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007032936A2 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
WO2008042571A2 (en) 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
WO2008157291A2 (en) * 2007-06-15 2008-12-24 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
CN102459221A (zh) * 2009-04-30 2012-05-16 住友化学株式会社 噻吩衍生物
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
CA2773615A1 (en) 2009-09-11 2011-03-17 Arwed Cleve Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
DK2523731T3 (en) 2010-01-14 2019-02-04 Novartis Ag Use of an adrenal hormone modifier
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
WO2014179564A1 (en) * 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
JP6156074B2 (ja) * 2013-11-08 2017-07-05 住友化学株式会社 スクシンイミド化合物及びその用途
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
PL3372584T3 (pl) * 2014-12-19 2021-07-05 Aragon Pharmaceuticals, Inc. Sposób wytwarzania związku diarylotiohydantoiny
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20200052995A (ko) * 2015-01-20 2020-05-15 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11279683B2 (en) 2016-12-29 2022-03-22 Enyo Pharma Thiophene derivatives as antiviral agents
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
EP4121044A4 (en) * 2020-03-20 2024-03-13 University Of Southern California REGULATION OF THE ANDROGEN RECEPTOR BY SMALL MOLECULE ENANTIOMERS
TW202208356A (zh) 2020-05-08 2022-03-01 美商哈利亞製藥公司 Ｎｅｋ７激酶抑制劑
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
WO2023154939A2 (en) * 2022-02-14 2023-08-17 The Johns Hopkins University Gcpii inhibition for the treatment of sarcopenia and aging
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3215597A (en) * 1963-10-30 1965-11-02 Dow Chemical Co Methods and compositions for use in animal husbandry
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
JPS63170383A (ja) * 1987-02-26 1988-07-14 Nippon Zeon Co Ltd 脂環式ジカルボン酸イミド化合物
CA2069318A1 (en) * 1989-10-27 1991-04-28 Engelbert Ciganek (n-phthalimidoalkyl) piperidines
CN1103769C (zh) * 1996-10-25 2003-03-26 第一制药株式会社 三环胺衍生物
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002533345A (ja) * 1998-12-22 2002-10-08 イーライ・リリー・アンド・カンパニー 置換三環式化合物
MXPA02012605A (es) * 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
BR0113980A (pt) * 2000-09-19 2003-06-24 Bristol Myers Squibb Co Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear

Also Published As

Publication number Publication date
JP2005523257A (ja) 2005-08-04
HUP0402554A3 (en) 2009-01-28
NZ533471A (en) 2007-05-31
PT1458723E (pt) 2008-12-26
PL370904A1 (pl) 2005-05-30
UA78265C2 (en) 2007-03-15
SI1458723T1 (sl) 2009-02-28
ATE411319T1 (de) 2008-10-15
RU2330038C2 (ru) 2008-07-27
HUP0402554A2 (hu) 2005-03-29
WO2003062241A8 (en) 2004-10-21
EP1458723A4 (en) 2005-12-21
GEP20063817B (en) 2006-05-10
WO2003062241A1 (en) 2003-07-31
HRP20040567A2 (en) 2005-06-30
TWI263640B (en) 2006-10-11
DK1458723T3 (da) 2009-02-09
YU53604A (sh) 2006-08-17
IS7324A (is) 2004-06-18
IL162547A0 (en) 2005-11-20
MXPA04005876A (es) 2005-05-16
TW200304810A (en) 2003-10-16
UY27595A1 (es) 2003-07-31
BR0215281A (pt) 2004-10-19
CO5640082A2 (es) 2006-05-31
CN1589271A (zh) 2005-03-02
EP1458723A1 (en) 2004-09-22
ZA200404812B (en) 2005-08-26
ES2314127T3 (es) 2009-03-16
AU2002361785B2 (en) 2008-05-22
KR20040086248A (ko) 2004-10-08
AR037950A1 (es) 2004-12-22
DE60229435D1 (de) 2008-11-27
CA2471342A1 (en) 2003-07-31
EP1458723B1 (en) 2008-10-15
RU2004122403A (ru) 2005-05-27

Similar Documents

Publication Publication Date Title
NO20043068L (no) Kondenserte heterocykliske succinimidforbindelser og analoger derav, modulatorer for nukleaer hormonreseptorfunksjon
DK1319007T3 (da) Kondenserede heterocykliske succinimidforbindelser og analoger deraf, modulatorer af nukleær hormonreceptorfunktion
EP1379249A4 (en) Attached Cytic Succinimide Compounds and Analogs Thereof, Nuclear Hormone Regenerative Function Modulators
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DK1139891T3 (da) Anordning til udvendig fiksering af knoglebrud, især brud på ankelen
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
EE200300524A (et) Ühendid, mis on CB2-retseptori agonistid, neid sisaldavad ravimkoostised ja nimetatud ühendite kasutamine ravis
DK1339335T3 (da) Indretning til fiksering af knogler, især af hvirvellegemer i forhold til hinanden
NO20014593L (no) Kjemokinreseptor bindende heterocykliske forbindelser
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
NO20014134D0 (no) Forbindelser med kondensert ring og anvendelse derav som legemidler
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
HUP0402672A3 (en) Fused cyclic modulators of nuclear hormone receptor function
ITMI20031175A1 (it) Procedimento per controllare ponti convertitori per
DK1228751T3 (da) Pulverformig sammensætning til affarvning af humane keratinfibre
PT1347760E (pt) Composicoes farmaceuticas de agonista do receptor de nmda
NO20026167L (no) Kondenserte cykliske forbindelser som modulatorer av nukle¶r hormon reseptor funksjon
DK1383733T3 (da) Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
DK1458438T3 (da) Apparat til injektion af lægemidler
DK1140931T3 (da) 5HT1-antagonister til antidepressiv behandling
DK0998470T3 (da) Fremgangsmåde til fremstilling af aminderivater af alkyloxyfuranon, forbindelser fremstillet ved denne fremgangsmåde og anvendelse af disse forbindelser
DE60036670D1 (de) Schaltung zur Sin(x)/x-Kompensation
DK1281707T3 (da) Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
ATE305925T1 (de) Positive modulatoren von nicotinrezeptor- agonisten
SI1319007T1 (sl) Kondenzirane heterociklicne sukcinimidne spojine in njihovi analogi, modulatorji funkcije nuklearnega hormonskega receptorja

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application